Within older Veterans, multiple factors may contribute to cognitive difficulties. Beyond Alzheimer’s disease (AD), psychiatric (e.g., PTSD) and health comorbidities (e.g., TBI) may also impact cognition.
Objective:
This study aimed to derive subgroups based on objective cognition, subjective cognitive decline (SCD), and amyloid burden, and then compare subgroups on clinical characteristics, biomarkers, and longitudinal change in functioning and global cognition.
Methods:
Cluster analysis of neuropsychological measures, SCD, and amyloid PET was conducted on 228 predominately male Vietnam-Era Veterans from the Department of Defense-Alzheimer’s Disease Neuroimaging Initiative. Cluster-derived subgroups were compared on baseline characteristics as well as 1-year changes in everyday functioning and global cognition.
Results:
The cluster analysis identified 3 groups. Group 1 (n = 128) had average-to-above average cognition with low amyloid burden. Group 2 (n = 72) had the lowest memory and language, highest SCD, and average amyloid burden; they also had the most severe PTSD, pain, and worst sleep quality. Group 3 (n = 28) had the lowest attention/executive functioning, slightly low memory and language, elevated amyloid and the worst AD biomarkers, and the fastest rate of everyday functioning and cognitive decline.
CONCLUSIONS:
Psychiatric and health factors likely contributed to Group 2’s low memory and language performance. Group 3 was most consistent with biological AD, yet attention/executive function was the lowest score. The complexity of older Veterans’ co-morbid conditions may interact with AD pathology to show attention/executive dysfunction (rather than memory) as a prominent early symptom. These results could have important implications for the implementation of AD-modifying drugs in older Veterans.
ZhuCW, SanoM (2021) Demographic, health, and exposure risks associated with cognitive loss, Alzheimer’s disease and other dementias in US military Veterans. Front Psychiatry12, 610334.
WilliamsonV, StevelinkSAM, GreenbergK, GreenbergN (2018) Prevalence of mental health disorders in elderly U.S. military veterans: A meta-analysis and systematic review. Am J Geriatr Psychiatry26, 534–545.
YaffeK, VittinghoffE, LindquistK, BarnesD, CovinskyKE, NeylanT, KluseM, MarmarC (2010) Posttraumatic stress disorder and risk of dementia among US veterans. Arch Gen Psychiatry67, 608–613.
6.
KornblithE, BahorikA, LiY, PeltzCB, BarnesDE, YaffeK (2022) Traumatic brain injury, cardiovascular disease, and risk of dementia among older US Veterans. Brain Inj36, 628–632.
7.
MartinezS, YaffeK, LiY, ByersAL, PeltzCB, BarnesDE (2021) Agent Orange exposure and dementia diagnosis in US veterans of the Vietnam era. JAMA Neurol78, 473–477.
8.
ByersAL, CovinskyKE, BarnesDE, YaffeK (2012) Dysthymia and depression increase risk of dementia and mortality among older Veterans. Am J Geriatr Psychiatry20, 664–672.
9.
BarnesDE, KaupA, KirbyKA, ByersAL, Diaz-ArrastiaR, YaffeK (2014) Traumatic brain injury and risk of dementia in older veterans. Neurology83, 312–319.
10.
EdmondsEC, SmirnovDS, ThomasKR, GravesLV, BangenKJ, Delano-WoodL, GalaskoDR, SalmonDP, BondiMW (2021) Data-driven vs consensus diagnosis of MCI: Enhanced sensitivity for detection of clinical, biomarker, and neuropathologic outcomes. Neurology97, e1288–e1299.
11.
EdmondsEC, WeigandAJ, HattonSN, MarshallAJ, ThomasKR, AyalaDA, BondiMW, McDonaldCR (2020) Patterns of longitudinal cortical atrophy over 3 years in empirically derived MCI subtypes. Neurology94, e2532–e2544.
12.
BlankenAE, JangJY, HoJK, EdmondsEC, HanSD, BangenKJ, NationDA (2020) Distilling heterogeneity of mild cognitive impairment in the National Alzheimer Coordinating Center database using latent profile analysis. JAMA Netw Open3, e200413.
13.
LamarM, DrabickD, BootsEA, AgarwalP, EmraniS, Delano-WoodL, BondiMW, BarnesLL, LibonDJ (2021) Latent profile analysis of cognition in a non-demented diverse cohort: A focus on modifiable cardiovascular and lifestyle factors. J Alzheimers Dis82, 1833–1846.
14.
ThomasKR, BangenKJ, WeigandAJ, OrtizG, WalkerKS, SalmonDP, BondiMW, EdmondsEC (2022) Cognitive heterogeneity and risk of progression in data-driven subtle cognitive decline phenotypes. J Alzheimers Dis90, 323–331.
15.
VogelJW, YoungAL, OxtobyNP, SmithR, OssenkoppeleR, StrandbergOT, La JoieR, AksmanLM, GrotheMJ, Iturria-MedinaY, PontecorvoMJ, DevousMD, RabinoviciGD, AlexanderDC, LyooCH, EvansAC, HanssonO (2021) Four distinct trajectories of tau deposition identified in Alzheimer’s disease. Nat Med27, 871–881.
HabesM, SotirasA, ErusG, ToledoJB, JanowitzD, WolkDA, ShouH, BryanNR, DoshiJ, VölzkeH (2018) White matter lesions: Spatial heterogeneity, links to risk factors, cognition, genetics, and atrophy. Neurology91, e964–e975.
18.
HabesM, GrotheMJ, TuncB, McMillanC, WolkDA, DavatzikosC (2020) Disentangling heterogeneity in Alzheimer’s disease and related dementias using data-driven methods. Biol Psychiatry88, 70–82.
19.
EdmondsEC, EppigJ, BondiMW, LeydenKM, GoodwinB, Delano-WoodL, McDonaldCR (2016) Heterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria. Neurology87, 2108–2116.
20.
BangenKJ, ClarkAL, WerhaneM, EdmondsEC, NationDA, EvangelistaN, LibonDJ, BondiMW, Delano-WoodL (2016) Cortical amyloid burden differences across empirically-derived mild cognitive impairment subtypes and interaction with APOE ɛ4 genotype. J Alzheimers Dis52, 849–861.
21.
ThomasKR, EdmondsEC, Delano-WoodL, BondiMW (2017) Longitudinal trajectories of informant-reported daily functioning in empirically defined subtypes of mild cognitive impairment. J Int Neuropsychol Soc23, 521–527.
22.
WeinerMW, VeitchDP, HayesJ, NeylanT, GrafmanJ, AisenPS, PetersenRC, JackC, JagustW, TrojanowskiJQ, ShawLM, SaykinAJ, GreenRC, HarveyD, TogaAW, FriedlKE, PacificoA, ShelineY, YaffeK, MohlenoffB,
Department of Defense Alzheimer’s Disease Neuroimaging Initiative
(2014) Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement10, S226–S235.
23.
WeinerMW, HarveyD, LandauSM, VeitchDP, NeylanTC, GrafmanJH, AisenPS, PetersenRC, JackCRJr, TosunD, ShawLM, TrojanowskiJQ, SaykinAJ, HayesJ, De CarliC, for the Alzheimer’s Disease Neuroimaging Initiative and the Department of Defense Alzheimer’s Disease Neuroimaging Initiative (2023) Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer’s disease pathology measured with biomarkers. Alzheimers Dement19, 884–895.
24.
ThomasKR, EdmondsEC, EppigJS, WongCG, WeigandAJ, BangenKJ, JakAJ, Delano-WoodL, GalaskoDR, SalmonDP, EdlandSD, BondiMW (2019) MCI-to-normal reversion using neuropsychological criteria in the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement15, 1322–1332.
25.
FariasST, MungasD, ReedBR, Cahn-WeinerD, JagustW, BaynesK, DeCarliC (2008) The measurement of everyday cognition (ECog): Scale development and psychometric properties. Neuropsychology22, 531–544.
26.
LandauSM, MintunMA, JoshiAD, KoeppeRA, PetersenRC, AisenPS, WeinerMW, JagustWJ,
Initiative for the ADN
(2012) Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol72, 578–586.
27.
WeigandAJ, MaassA, EglitGL, BondiMW (2022) What’s the cut-point? A systematic investigation of tau PET thresholding methods. Alzheimers Res Ther14, 49.
28.
NationDA, EdlandSD, BondiMW, SalmonDP, Delano-WoodL, PeskindER, QuinnJF, GalaskoDR (2013) Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology81, 2024–2027.
WeathersFW, RuscioAM, KeaneTM (1999) Psychometric properties of nine scoring rules for the Clinician-Administered Posttraumatic Stress Disorder Scale. Psychol Assess11, 124–133.
31.
O’BryantSE, LacritzLH, HallJ, WaringSC, ChanW, KhodrZG, MassmanPJ, HobsonV, CullumCM (2010) Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer’s coordinating center database. Arch Neurol67, 746–749.
32.
VeitchDP, FriedlKE, WeinerMW (2013) Military risk factors for cognitive decline, dementia and Alzheimer’s disease. Curr Alzheimer Res10, 907–930.
33.
YaffeK, HoangTD, ByersAL, BarnesDE, FriedlKE (2014) Lifestyle and health-related risk factors and risk of cognitive aging among older veterans. Alzheimers Dement10, S111–S121.
34.
PrietoS, NolanKE, MoodyJN, HayesSM, HayesJP; Department of Defense Alzheimer’s Disease Neuroimaging Initiative (2023) Posttraumatic stress symptom severity predicts cognitive decline beyond the effect of Alzheimer’s disease biomarkers in Veterans. Transl Psychiatry13, 102.
35.
KuringJK, MathiasJL, WardL (2020) Risk of dementia in persons who have previously experienced clinically-significant depression, anxiety, or PTSD: A systematic review and meta-analysis. J Affect Disord274, 247–261.
36.
JakAJ, CrockerLD, AupperleRL, ClausenA, BomyeaJ (2018) Neurocognition in PTSD: Treatment insights and implications. In Behavioral Neurobiology of PTSD,Vermetten E, Baker DG, Risbrough VB, eds. Springer International Publishing, Cham, pp. 93-116.
37.
JakAJ, JurickS, CrockerLD, Sanderson-CiminoM, AupperleR, RodgersCS, ThomasKR, BoydB, NormanSB, LangAJ, KellerAV, SchiehserDM, TwamleyEW (2019) SMART-CPT for veterans with comorbid post-traumatic stress disorder and history of traumatic brain injury: A randomised controlled trial. J Neurol Neurosurg Psychiatry90, 333–341.
SalmonDP, BondiMW (2009) Neuropsychological assessment of dementia. Annu Rev Psychol60, 257–282.
41.
WeigandAJ, BangenKJ, ThomasKR, Delano-WoodL, GilbertPE, BrickmanAM, BondiMW,
Alzheimer’s Disease Neuroimaging Initiative
(2020) Is tau in the absence of amyloid on the Alzheimer’s continuum? A study of discordant PET positivity. Brain Commun2, fcz046.
42.
VogelJW, HanssonO (2022) Subtypes of Alzheimer’s disease: Questions, controversy, and meaning. Trends Neurosci45, 342–345.
